The $200 billion patent cliff bearing down on Big Pharma through 2030 is not primarily a manufacturing or regulatory problem. […]

The patent cliff is not a metaphor. When Humira’s U.S. composition-of-matter patent finally cracked open in 2023, AbbVie had already

A single composition-of-matter patent can represent $40 billion in franchise value. At the Patent Trial and Appeal Board (PTAB), that

A Paragraph IV filing is not a legal emergency. It is a predictable business event built into the architecture of

Pharmaceutical value is not built exclusively in the laboratory. It is won and lost on the global chessboard of intellectual

KSR killed your obviousness defense. Amgen killed your functional claims. Here is the complete IP architecture for winning anyway, from

Part I — The Foundational Divide Why Biologic IP is a Different Discipline Entirely Before building any patent strategy, a

A brand-name drug loses 90% of its market share within 12 months of generic entry. That single data point explains

The IP landscape for small molecule drugs has never been harder to defend. R&D costs now exceed $2.23 billion per